Skip to Main Content

Spring classes begin Jan. 25 as fully remote, 25% transition to in-person Feb. 1. For more information, visit COVID website.

Drug Makers Will Focus on Sourcing



Assoc. Prof. Carl Lawton of the Department of Chemical Engineering expects changes to drug development and the biopharmaceutical manufacturing process as a result of the pandemic.

“Supply chains will be examined in detail and some will be sourced to the U.S. where possible. Quality and non-interruption of the supply chain will be a primary consideration,” says Lawton, who is director of the Massachusetts Biomanufacturing Center at UMass Lowell. 

“Several companies are already allotting more resources and utilizing novel approaches to vaccine research as a result of COVID-19. These should accelerate,” he says.  

Developing vaccines is one thing, but convincing the general public to trust their safety and efficacy is another.

“Public demonstrations of leading figures – such as former presidents, famous athletes and entertainers – getting the shot is important. Moving forward, introduction about the science and safety of vaccines should be done in grades K-12,” says Lawton.